(19)
(11) EP 3 639 828 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
05.01.2022 Bulletin 2022/01

(45) Mention of the grant of the patent:
01.12.2021 Bulletin 2021/48

(21) Application number: 19214560.5

(22) Date of filing: 23.12.2014
(51) International Patent Classification (IPC): 
A61K 31/568(2006.01)
A61K 31/56(2006.01)
A61P 1/16(2006.01)
 A61K 31/575(2006.01)
A61P 43/00(2006.01)
A61K 35/12(2015.01)
(52) Cooperative Patent Classification (CPC):
A61K 31/568; A61P 1/16; A61K 31/575

(54)

USE OF OXYGENATED CHOLESTEROL SULFATES (OCS) FOR TREATING ACUTE LIVER FAILURE

VERWENDUNG VON OXYGENIERTEN CHOLESTERINSULFATEN (OCS) ZUR BEHANDLUNG AKUTEM LEBERVERSAGEN

UTILISATIONS DE SULFATES DE CHOLESTÉROL OXYGÉNÉS (OCS) POUR TRAITER L´INSUFFISANCE HÉPATIQUE AIGUE

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30) Priority: 24.12.2013 US 201361920617 P

(43) Date of publication of application:
22.04.2020 Bulletin 2020/17

(62) Application number of the earlier application in accordance with Art. 76 EPC:
14874617.5 / 3086793

(73) Proprietors:
  • Virginia Commonwealth University
    Richmond, VA 23298 (US)
  • The United States Government as Represented by The Department of Veterans Affairs
    Washington, DC 20420 (US)
  • Durect Corporation
    Cupertino, CA 95014 (US)

(72) Inventors:
  • REN, Shunlin
    Richmond, VA Virginia 23249 (US)
  • THEEUWES, Felix
    Los Altos Hills, CA California 94022 (US)
  • BROWN, James E.
    Los Gatos, CA California 95032 (US)
  • LIN, WeiQi
    Emerald Hills, VA Virginia 94062 (US)

(74) Representative: J A Kemp LLP 
80 Turnmill Street
London EC1M 5QU
London EC1M 5QU (GB)


(56) References cited: : 
US-A1- 2012 264 816
   
  • Xu Leyuan ET AL: "25-Hydroxycholesterol-3-Sulfate Decreases Hepatic Steatosis and Inflammation in Mouse Models of Nonalcoholic Fatty Liver Disease by Down-Regulating Sterol Regulatory Element Binding Protein-1c", , 1 May 2011 (2011-05-01), XP055386695, Retrieved from the Internet: URL:http://metcorner.gastro.org/article/S0 016-5085(11)64071-7/pdf [retrieved on 2017-06-29]
  • L. XU ET AL: "5-Cholesten-3 ,25-Diol 3-Sulfate Decreases Lipid Accumulation in Diet-Induced Nonalcoholic Fatty Liver Disease Mouse Model", MOLECULAR PHARMACOLOGY, vol. 83, no. 3, 1 March 2013 (2013-03-01), pages 648-658, XP055230805, US ISSN: 0026-895X, DOI: 10.1124/mol.112.081505
  • DATABASE BIOSIS [Online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; July 1998 (1998-07), BERNAL WILLIAM ET AL: "Tumor necrosis factor genomic polymorphism and outcome of acetaminophen (paracetamol)-induced acute liver failure", Database accession no. PREV199800371936 & BERNAL WILLIAM ET AL: "Tumor necrosis factor genomic polymorphism and outcome of acetaminophen (paracetamol)-induced acute liver failure", JOURNAL OF HEPATOLOGY, vol. 29, no. 1, July 1998 (1998-07), pages 53-59, ISSN: 0168-8278
 
Remarks:
The file contains technical information submitted after the application was filed and not included in this specification
 
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).